{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:10:52Z","timestamp":1780791052374,"version":"3.54.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:sec xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              The American College of Cardiology (ACC) and European Society of Cardiology\/European Atherosclerosis Society (ESC\/EAS) have recently published recommendations for the use of proprotein convertase subtilisin\/kexin\u20109 (\n              <jats:styled-content style=\"fixed-case\">PCSK<\/jats:styled-content>\n              9) inhibitors in\u00a0situations of very high risk. We aim to assess in the real world the suitability of\n              <jats:styled-content style=\"fixed-case\">PCSK<\/jats:styled-content>\n              9 inhibitors for acute coronary syndromes.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              We analyzed a prospective Swiss cohort of 2023 patients hospitalized for acute coronary syndromes between 2009 and 2014 with available data for low\u2010density lipoprotein cholesterol and lipid\u2010lowering therapy at 1\u00a0year. Clinical familial hypercholesterolemia was defined using the Dutch Lipid Clinic Network algorithm as unlikely, possible, probable, or definite. We simulated a fixed relative reduction of 24% in low\u2010density lipoprotein cholesterol levels at 1\u00a0year in all patients not treated with ezetimibe, irrespective of the low\u2010density lipoprotein cholesterol levels and statin regimen. At 1\u00a0year, 94.3% of patients were treated with statin, 5.8% with ezetimibe, and 35.8% of patients had on\u2010target low\u2010density lipoprotein cholesterol levels (&lt;1.8\u00a0mmol\/L); 25.6% met criteria for possible or probable\/definite familial hypercholesterolemia. After a simulation of the lipid\u2010lowering effect of ezetimibe, the proportion of patients who would be eligible for\n              <jats:styled-content style=\"fixed-case\">PCSK<\/jats:styled-content>\n              9 inhibitors at 1\u00a0year was 13.4% using American College of Cardiology criteria and 2.7% using European Society of Cardiology\/European Atherosclerosis Society criteria. Patients with possible or probable\/definite familial hypercholesterolemia were more eligible for\n              <jats:styled-content style=\"fixed-case\">PCSK<\/jats:styled-content>\n              9 inhibitors compared with their non\u2013familial hypercholesterolemia counterparts: 27.6% versus 8.8% according to American College of Cardiology criteria and 6.6% versus 1.8% according to European Society of Cardiology\/European Atherosclerosis Society criteria (\n              <jats:italic>P<\/jats:italic>\n              &lt;0.001).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              Recommendations made by the American College of Cardiology guidelines would lead to 5\u2010fold higher eligibility rates for\n              <jats:styled-content style=\"fixed-case\">PCSK<\/jats:styled-content>\n              9 inhibitors compared to the European Society of Cardiology\/European Atherosclerosis Society consensus statement in acute coronary syndrome patients.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.117.006537","type":"journal-article","created":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T01:10:22Z","timestamp":1510276222000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":29,"title":["Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology\/European Atherosclerosis Society (ESC\/EAS) Guidelines After Acute Coronary Syndromes"],"prefix":"10.1161","volume":"6","author":[{"given":"Baris","family":"Gencer","sequence":"first","affiliation":[{"name":"Division of Cardiology, Geneva University Hospital, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos C.","family":"Koskinas","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"R\u00e4ber","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexios","family":"Karagiannis","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit Bern and Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nanchen","sequence":"additional","affiliation":[{"name":"Department of Ambulatory Care and Community Medicine, University of Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reto","family":"Auer","sequence":"additional","affiliation":[{"name":"Institute of Primary Health Care (BIHAM), University of Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Carballo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Geneva University Hospital, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Carballo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Geneva University Hospital, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Klingenberg","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Heart Center, University Hospital Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dik","family":"Heg","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit Bern and Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Matter","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Heart Center, University Hospital Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"L\u00fcscher","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Heart Center, University Hospital Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Rodondi","sequence":"additional","affiliation":[{"name":"Institute of Primary Health Care (BIHAM), University of Bern, Switzerland"},{"name":"Department of General Internal Medicine, University Hospital of Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mach","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Geneva University Hospital, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu505"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv320"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.08.018"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2014.12.049"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2014.12.014"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2957"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv563"},{"key":"e_1_3_5_11_2","first-page":"2245","article-title":"European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk","volume":"38","author":"Landmesser U","year":"2017","unstructured":"Landmesser U, John Chapman M, Farnier M, Gencer B, Gielen S, Hovingh GK, Luscher TF, Sinning D, Tokgozoglu L, Wiklund O, Zamorano JL, Pinto FJ, Catapano AL. European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J. 2017;38:2245\u20132255.","journal-title":"Eur Heart J"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501031"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500858"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.519"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv289"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv637"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.023007"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.12.020"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000311"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv043"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.117.006537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:40:30Z","timestamp":1715596830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.117.006537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1161\/JAHA.117.006537"],"URL":"https:\/\/doi.org\/10.1161\/jaha.117.006537","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"2017-05-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e006537"}}